Illumina and Labcorp Deepen Oncology Testing Partnership to Expand Access
Event summary
- Illumina and Labcorp expanded their collaboration on March 18, 2026, to advance precision oncology through next-generation sequencing (NGS) solutions.
- The partnership aims to promote equitable access to cancer biomarker testing, generate evidence for payer coverage, and develop new tests for unmet needs.
- The companies will co-commercialize Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx and Illumina's FDA-approved TruSight™ Oncology Comprehensive for solid tumor profiling.
- A collaborative study published in Frontiers of Oncology evaluated over 7,600 non-small cell lung cancer (NSCLC) tumor samples, demonstrating the utility of Illumina CGP in detecting genomic features.
The big picture
This expanded collaboration between Illumina and Labcorp underscores the growing emphasis on precision oncology and the need for equitable access to advanced genomic testing. The partnership aims to bridge existing testing gaps and support the development of companion diagnostics for targeted therapies, reflecting broader industry trends towards personalized cancer care. The scale of their joint efforts, including eight publications and 18 conference presentations since 2022, highlights the strategic importance of this collaboration in advancing oncology research and clinical applications.
What we're watching
- Market Expansion
- How the co-commercialization of distributed IVD test kits will affect access to advanced biomarker testing in hospitals and community health systems.
- Regulatory Dynamics
- Whether the joint efforts to demonstrate clinical utility of CGP will facilitate broader payer coverage and adoption.
- Innovation Pace
- The pace at which Illumina and Labcorp can develop new tests to address unmet needs in precision oncology.
Related topics